CathWorks FFRangio System
AI-powered, drug-free and wire-free physiologic assessment for coronary arteries
Software · EmbeddedCompany source
Company profile
About CathWorks Ltd
CathWorks is a global leader in digital health innovations focused on transforming how cardiovascular disease is diagnosed and treated. The company's flagship product, the CathWorks FFRangio System, combines artificial intelligence and advanced computational science to obtain physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. The system provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree, enabling comprehensive physiologic assessment across multiple vessels. The FFRangio System delivers real-time FFRangio values at every point on the coronary tree, simulated pullback curves to differentiate functional patterns of coronary artery disease, and integrated sizing tools for non-invasive lesion measurements. The technology has been adopted by major health systems across the United States and internationally, with institutions like Lenox Hill Hospital performing over 1,000 cases. CathWorks is now part of Medtronic, expanding its reach to improve patient outcomes globally. The company is dedicated to partnering with physicians to improve patient health through innovative cardiovascular diagnostic solutions.
Company description CathWorks Ltd official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at CathWorks Ltd?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiovascular disease
- Coronary artery disease
- Coronary lesions requiring physiologic assessment
Who it serves
- Catheterization Laboratories
- Health Systems
- Hospitals
- Interventional Cardiology Departments
Deployment & integration
Embedded deployment with recorded integration context.
Geographic context
MarketsEurope · Israel · Japan · United States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by Medtronic (2025), ALL-RISE Global Study completed enrollment of 1,927 patients (2025), PROVISION Trial results presented at ACC.26 (2025), EU-MDR approval received (2024), 4th generation FFRangio System launched (2021), Lenox Hill Hospital reached 1,000 FFRangio cases milestone
Partnerships
Recorded partners
- AdventHealth
- Hackensack Meridian Health
- Lehigh Valley Health Network
- Lenox Hill Hospital
- Medtronic (acquired by)
- Northwell Health
- T.J. Samson Hospital
- VA Long Beach Healthcare System
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Validation Study of Image-Based Fractional Flow Reserve During Coronary Angiography.Circulation. Cardiovascular interventions · Sep 1, 2017
Clinical validation
Clinical-trial records
Advancing Cath Lab Results With FFRangio Coronary Physiology AssessmentNCT05893498 · Sponsor · ACTIVE NOT RECRUITING
FFRangio Accuracy vs. Standard FFRNCT03226262 · Sponsor · COMPLETED
Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel DiseaseNCT03455244 · Sponsor · COMPLETED
Angiogram Based Fractional Flow Reserve FFRangio - A Validation StudyNCT03005028 · Sponsor · COMPLETED
Regulatory
Regulatory records
FFRangioK192442 · 510k · Dec 9, 2019
FFRangio SystemK182149 · 510k · Dec 19, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Similar clinical outcomes to invasive wire-based FFR
PROVISION Trial and ALL-RISE study results
Elimination of drug stimulation and pressure wires
Non-invasive physiologic assessment
Multi-vessel assessment capability
Entire coronary tree evaluation in single procedure
AdventHealth Flagler County
AI-driven technology implementation to improve heart care
Improved heart health care delivery in Flagler County
Hackensack Meridian Health
Integration of CathWorks FFRangio System for coronary artery disease assessment
System-wide adoption announced; FFRangio accelerated culture of collaboration in cath lab
Hackensack Meridian Health, Mountainside Medical Center
Accelerated culture of collaboration in cath lab with FFRangio technology
Improved cath lab collaboration
Lehigh Valley Health Network
Advanced procedural modeling and comprehensive data integration for precision-driven decision-making
Enhanced workflow efficiency, optimized procedural planning, and better patient outcomes
Lenox Hill Hospital
First in US to perform 1,000 FFRangio cases for coronary physiologic assessment
1,000 FFRangio cases completed - historic milestone
Northwell Health
Comprehensive hemodynamics and physiology assessment for better patient understanding
More detailed assessment compared to quick lesion evaluation, improving physician collaboration
T.J. Samson Hospital
AI-powered heart testing with less invasive approach for accurate cardiac data
More accurate data in a less invasive way
VA Long Beach Healthcare System
Non-invasive diagnostic assessment with similar accuracy to invasive measures
Similar diagnostic accuracy and outcomes without need for wires or adenosine
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from CathWorks Ltd
Recent articles published on CathWorks Ltd's official website.
Recent Posts
Read on CathWorks LtdLate-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through 2 Years
Read on CathWorks LtdRole of CathWorks FFRangio for the Assessment of Coronary Artery Disease Now Reinforced by SCAI Expert Opinion
Read on CathWorks LtdAs Featured in Cardiac Wire: CathWorks FFRangio Goes Beyond Physiology
Read on CathWorks LtdCathWorks FFRangio: Proven Outcomes without Compromise or Complications (TCT 2025, San Francisco, CA)
Read on CathWorks Ltd07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.